BioTuesdays

Category - Developments

IntelGenx Logo

IntelGenx, Chemo Group sign CNS accord

IntelGenx Technologies (OTCQX:IGXT; TSX-V:IGX) has signed a definitive agreement with Chemo Group for the co-development and commercialization of a generic tablet in the area of CNS on a worldwide basis. According to...

Titan Pharmaceuticals Logo

Braeburn files for $150-million IPO

Closely held Braeburn Pharmaceuticals filed with U.S. regulators to raise up to $150-million in an initial public offering, seven months after its Probuphine implant to treat opioid addiction was approved by the FDA...

IntelGenx Logo

IntelGenx in development pact with Endo

IntelGenx (OTCQX:IGXT; TSX-V:IGX) entered into a co-development and commercialization agreement with Endo Ventures for a new product utilizing IntelGenx’ proprietary VersaFilm for the USA market. Under the accord...

Dipexium Pharmaceuticals

Dipexium, PLx Pharma agree to merge

Dipexium Pharmaceuticals (NASDAQ:DPRX) and closely held PLx Pharma have agreed to merge in an all-stock transaction.  Following closing, Dipexium will be renamed PLx Pharma and will operate under the leadership of...

microbix

Microbix Q4 revenue jumps 64% to new record

Sales for Microbix Biosystems (TSX:MBX) in the fourth quarter of fiscal 2016 climbed 64% to $3.5-million, representing the highest quarterly revenue ever achieved by the company, from $2.1-million a year earlier. Net...

Arbutus Biopharma Logo

Arbutus, Spring Bank in HBV collaboration

Arbutus Biopharma (NASDAQ:ABUS) and Spring Bank Pharmaceuticals (NASDAQ:SBPH) agreed to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV). The accord involves the co-administration of Spring...

Adamis Pharma

Adamis resubmits NDA to FDA for epinephrine pen

Adamis Pharmaceuticals (NASDAQ:ADMP) has resubmitted its NDA to the FDA for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis. The resubmission is intended to address...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.